Control of poorly immunogenic tumors with systemic STING agonist-loaded liposomes targeting cross-presenting dendritic cells
{{output}}
Objectives: Cancer vaccines combine tumor antigen and adjuvant to drive an anti-tumor immune response. Clec9A-targeted nanoparticles directing CD4 and CD8 neo-epitopes to cross-presenting dendritic cells (DCs) stimulate adjuvant-... ...
